‘Epigenetic Engineering’ Gene Therapy From Epic Bio Shows Early Promise

Progress For Non-Cutting CRISPR Technology

The San Francisco-based company has taken a step forward with proof of concept for its ‘switch on or switch off’ approach to gene regulation via non-cutting CRISPR molecules.

DNA — Epic Bio is focused on epigenetics - turning on or off existing genes, rather than editing or replacing them as with other approaches. • Source: Shutterstock

Epic Bio has presented early data from its non-cutting CRISPR technology which aims to overcome limitations of existing gene therapies and turn on or off disease-related genes.

The company was launched last July by CRISPR co-inventor Stanley Qi with a $55m backing from investors to develop its...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

AbbVie Licenses IGI’s ISB 2001 In Second Myeloma Trispecific Deal For 2025

10 Jul 2025

• By Alaric DeArment

IGI CEO Cyril Konto said in an interview that his company picked AbbVie for its agility, drug development acumen and expertise in areas like intellectual property and legal affairs.